公开(公告)号：US10294229B2

公开(公告)日：2019-05-21

申请号：US15738362

申请日：2016-06-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Daniel S. Gardner ,  Joseph B. Santella ,  Venkatram Reddy Paidi ,  Hong Wu ,  John V. Duncia ,  Satheesh Kesavan Nair ,  John Hynes ,  Xiao Zhu

IPC: A61K31/437 ,  A61K31/519 ,  A61P29/00 ,  C07D487/04 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein HET is a heteroaryl selected from pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3 d]pyrimidinyl, pyrazolo[3,4 b]pyridinyl, pyrazolo[3,4 d]pyrimidinyl, imidazolo[4,5 b]pyridinyl, and imidazolo[4,5 d]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a nitrogen ring atom in said heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; A is pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxadiazolyl or dihydroisoxazolyl, each substituted with zero or 1 Ra; and R3, Ra, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

公开(公告)号：US11351164B2

公开(公告)日：2022-06-07

申请号：US16328473

申请日：2017-08-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Liping Zhang ,  Emily Charlotte Cherney ,  James Aaron Balog ,  Xiao Zhu

IPC: A61K31/4709 ,  A61K39/395 ,  C07D401/08 ,  C07D401/12 ,  C07D413/08 ,  C07D413/12 ,  C07D413/14 ,  C07D417/08 ,  C07D417/12 ,  C07D417/14

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compound and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

公开(公告)号：US20200270298A1

公开(公告)日：2020-08-27

申请号：US16642440

申请日：2018-08-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Lalgudi S. HARIKRISHNAN ,  Muthoni G. Kamau ,  Xiao Zhu

IPC: C07H21/02 ,  C07K16/28

Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US11066392B2

公开(公告)日：2021-07-20

申请号：US16612076

申请日：2018-05-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron Balog ,  Emily Charlotte Cherney ,  Liping Zhang ,  Audris Huang ,  Weifang Shan ,  David K. Williams ,  Xiao Zhu ,  Weiwei Guo

IPC: A61P35/00 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/4375 ,  A61K31/497 ,  A61K31/506 ,  C07D401/12 ,  C07D403/12 ,  C07D471/04 ,  C07D213/85

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

公开(公告)号：US20180186799A1

公开(公告)日：2018-07-05

申请号：US15738362

申请日：2016-06-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Daniel S. GARDNER ,  Joseph B. Santella ,  Venkatram Reddy Paidi ,  Hong Wu ,  John V. Duncia ,  Satheesh Kesavan Nair ,  John Hynes ,  Xiao Zhu

IPC: C07D487/04 ,  C07D471/04

CPC classification number: C07D487/04 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein HET is a heteroaryl selected from pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3 d]pyrimidinyl, pyrazolo[3,4 b]pyridinyl, pyrazolo[3,4 d]pyrimidinyl, imidazolo[4,5 b]pyridinyl, and imidazolo[4,5 d]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a nitrogen ring atom in said heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; A is pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxadiazolyl or dihydroisoxazolyl, each substituted with zero or 1 Ra; and R3, Ra, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

公开(公告)号：US11667663B2

公开(公告)日：2023-06-06

申请号：US16642440

申请日：2018-08-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Lalgudi S. Harikrishnan ,  Muthoni G. Kamau ,  Xiao Zhu

IPC: C07H21/02 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07H21/02 ,  C07K16/2818 ,  A61K2039/505

Abstract: The present invention is directed to compounds of the formula




wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US20230167131A1

公开(公告)日：2023-06-01

申请号：US17799028

申请日：2021-02-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Kumaravel Selvakumar ,  Venkatram Paidi ,  Srinivasan Thangathirupathy ,  Vijaya Kumar Cm ,  Tirupathi Rao Alajangi ,  Mallikarjun Reddy Sura ,  Krishna Mahadevu ,  Ramesh Kumar Sistla ,  Piyush Agarwal ,  Arul Mozhi Subbiah Karuppiah ,  Jalathi S. Nair ,  Ooha Morampudi ,  Manoranjan Panda ,  Joseph A. Tino ,  Robert J. Cherney ,  John V. Duncia ,  Daniel S. Gardner ,  T. G. Murali Dhar ,  Audrey Graham Ross ,  Paul E. Gormisky ,  Xiao Zhu ,  Boris M. Seletsky ,  Alyssa H. Antropow ,  Deqiang Niu ,  Zhengdong Zhu ,  Guobin Miao ,  Julio Herman Cuervo

IPC: C07D519/00 ,  C07D471/04 ,  C07D487/04 ,  C07D409/14 ,  C07D405/14 ,  C07D413/14

CPC classification number: C07D519/00 ,  C07D471/04 ,  C07D487/04 ,  C07D409/14 ,  C07D405/14 ,  C07D413/14

Abstract: The disclosure generally relates to substituted heterocyclic compounds of Formula (Ia), which are inhibitors of PAD4, method for preparing these compounds, pharmaceutical compositions comprising these compounds and use of these compounds in the treatment of a disease or a disorder associated with PAD4 enzyme activity.

公开(公告)号：US11203592B2

公开(公告)日：2021-12-21

申请号：US16754175

申请日：2018-10-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven P. Seitz ,  Emily Charlotte Cherney ,  Xiao Zhu

IPC: C07D471/04 ,  C07D307/94 ,  C07D405/06 ,  C07K16/28

Abstract: The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.